Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
This organization files only for itself — no outside firm has reported fees for it.
Reported as lobbying expenses
Money reported as spent on lobbying rather than as a fee paid to an outside firm. See the full list.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: gsk-fka-glaxosmithkline-inc.
Gsk (Fka Glaxosmithkline Inc.) — Receipts Report
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
68 filings
$81.1M on those filings
Trade (domestic/foreign)
TRD
62 filings
$71.7M on those filings
Budget/Appropriations
BUD
60 filings
$67.2M on those filings
Taxation/Internal Revenue Code
TAX
25 filings
$33M on those filings
Medical/Disease Research/Clinical Labs
MED
8 filings
$13.8M on those filings
Tariff (miscellaneous tariff bills)
TAR
8 filings
$8.5M on those filings
Government Issues
GOV
4 filings
$5.3M on those filings
Torts
TOR
2 filings
$2.5M on those filings
Defense
DEF
1 filing
$420K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
117th Congress
Prescription Drug Price Relief Act of 2021
10 filingsthrough 2022
H.R. 3117th CongressElijah E. Cummings Lower Drug Costs Now Act10 filingsthrough 2022
S. 154117th CongressReciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 202110 filingsthrough 2022
S. 164117th CongressAdvancing Education on Biosimilars Act of 202110 filingsthrough 2022
S. 259117th CongressSafe and Affordable Drugs from Canada Act of 202110 filingsthrough 2022
S. 415117th CongressA bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.10 filingsthrough 2022
S. 562117th CongressEnsuring Timely Access to Generics Act of 202110 filingsthrough 2022
S. 773117th CongressA bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.10 filingsthrough 2022
S. 920117th CongressAffordable and Safe Prescription Drug Importation Act10 filingsthrough 2022
H.R. 1873117th CongressAdvancing Education on Biosimilars Act of 20219 filingsthrough 2022
H.R. 1978117th CongressProtecting Seniors Through Immunization Act of 20219 filingsthrough 2022
H.R. 2071117th CongressMedicare Prescription Drug Price Negotiation Act of 20219 filingsthrough 2022
H.R. 2139117th CongressMedicare Drug Price Negotiation Act9 filingsthrough 2022
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
through 2025
Michael J CalvoGsk (Fka Glaxosmithkline Inc.)Covered position: Rep.Taylor NC11 LegCorp, 4/04-1/05 LA,1/05-8/06 SrLegAsst,8/06-1/07 Rep. McHenry PolAdv,1/07-8/07 Rep.Gingrey GA11 SrLegAsst,8/07-1/09 Sr Pol Adv,1/09-8/10 LD,8/10-3/12 DCofS,3/12-1/15 Rep. Hice LD,1/15-8/1637 filingsthrough 2025
Sarah J WalshGsk (Fka Glaxosmithkline Inc.)27 filingsthrough 2015
Gary HeimbergGsk (Fka Glaxosmithkline Inc.)27 filingsthrough 2015
Alec Rubio HinojosaGsk (Fka Glaxosmithkline Inc.)Covered position: Sen. Mike Enzi (R-WY), Intern: August 2013 - Dec 2013; Staff Assistant: Dec 2013 - March 2014; Sen. HELP Committee, Subcommittee on Primary Health and Retirement Security, Research Asst : March 2014 - Sept 201723 filingsthrough 2023
Curtis E RhyneGsk (Fka Glaxosmithkline Inc.)Covered position: Intrn,Rep.Virginia Foxx,1/09-4/09;Rsrch Asst,Rep.Tom Price,5/09-12/10;Prof Pol Staff,Rep. Jim Jordan,1/11-12/12;Sr Pol Adv,Rep.Steve Scalise,1/13-3/14;Leg Dir,Rep.Richard Hudson, 4/14-1/17;Dep Chief ofStaff,Leg Dir,Rep.Holding,8/17-4/2022 filingsthrough 2025
Joseph McgowanGsk (Fka Glaxosmithkline Inc.)Covered position: None20 filingsthrough 2017
Jonathan CauseyGsk (Fka Glaxosmithkline Inc.)Covered position: Chief of Staff, Cong. Larry Bucshon 1/11-10/15, Leg. Dir.,Sen. Elizabeth Dole 10/07-1/09, Chief of Staff, Cong. Patrick McHenry 1/05-10/07, Leg. Asst, Cong. Robin Hayes 3/02-12/04, Leg. Corp., Sen. Jesse Helms 6/01-3/0216 filingsthrough 2019
Monica CloudGsk (Fka Glaxosmithkline Inc.)Covered position: Rep. Sheila Jackson-Lee, Deputy Chief of Staff and Legislative Counsel, June 12, 2019 - January 10, 2020; Rep. Alma Adams, Chief of Staff, January 13, 2020 - September 31, 202015 filingsthrough 2025
Stephen ScangoGsk (Fka Glaxosmithkline Inc.)15 filingsthrough 2015
John Del GiornoGsk (Fka Glaxosmithkline Inc.)12 filingsthrough 2013
Jonathan E MartinezGsk (Fka Glaxosmithkline Inc.)Covered position: Leg. Dir, Rep. Nydia M. Velazquez, Nov 2019-March 2022; Sr Leg Asst, Rep. Nydia M. Velazquez, May 2017-Nov 2019; Leg Asst, October 2016-April 2017; Staff Asst, May 2014-Sept 2016 Comm on Small Business, Leg Dir, Oct 1, 2021-March 15, 20224 filingsthrough 2022
Sara Hart WeirGsk (Fka Glaxosmithkline Inc.)2 filingsthrough 2012
